
Author's Accepted Manuscript

Selecting the best haploidenitcal donor

Shannon R. McCurdy, Ephraim J. Fuchs



 PII:
 S0037-1963(16)30049-X

 DOI:
 http://dx.doi.org/10.1053/j.seminhematol.2016.08.001

 Reference:
 YSHEM50894

To appear in: Seminars in Hematology

Received date: 17 May 2016 Revised date: 3 August 2016 Accepted date: 8 August 2016

Cite this article as: Shannon R. McCurdy and Ephraim J. Fuchs, Selecting the best haploidenitcal donor, *Seminars in Hematology*, http://dx.doi.org/10.1053/j.seminhematol.2016.08.001

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Title: Selecting the Best Haploidenitcal Donor

Authors: Shannon R. McCurdy M.D.,^{1*} Ephraim J. Fuchs M.D.¹

Author Affiliations: ¹Johns Hopkins University, Baltimore, MD, United States

*Corresponding author; CRB I, 3M88 1650 Orleans Street, Baltimore, MD 21287; Phone 410-955-8893; Fax 410-955-0960 Email, smccurd2@jhmi.edu

Conflicts of Interest: The authors declare that they have no conflicts of interest or competing financial or personal relationships that could inappropriately influence the content of this article.

Abstract

The substantial evidence of the safety of human leukocyte antigen (HLA)-haploidentical (haplo) blood or marrow transplantation (BMT) has led to its increasing utilization. When prioritizing HLA-matched grafts, patients frequently have few or no donors from whom to choose. However, a given patient may have multiple suitable haplo donors. Therefore factors other than HLA-match become critical for selecting the best donor. We recommend a donor selection algorithm based on the donor-specific antibodies, ABO match, donor age, donor sex, and cytomegalovirus serostatus match. Despite provocative initial evidence, further studies are warranted to determine whether there is any benefit to selecting a haplo donor based on the number of HLA-mismatches, Natural Killer cell alloreactivity, or the presence of noninherited maternal HLA antigens. Download English Version:

https://daneshyari.com/en/article/5664436

Download Persian Version:

https://daneshyari.com/article/5664436

Daneshyari.com